Bhat; Smita

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bhat; Smita.The latest application filed is for "alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators".

Company Profile

0.15.10

Bhat; Smita - Irvine CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Selective subtype alpha 2 adrenergic agents and methods for use thereof Grant 8,809,379 - Heidelbaugh , et al. August 19, 2	2014-08-19
Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors Grant 8,735,438 - Sinha , et al. May 27, 2	2014-05-27
Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators Grant 8,541,397 - Sinha , et al. September 24, 2	2013-09-24
Alkyne And Alkene Derivatives As Sphingosine 1-phosphate-1 Receptor Modulators App 20130150331 - Sinha; Santosh C. ; et al.	2013-06-13
Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds Grant 8,309,729 - Sinha , et al. November 13, 2	2012-11-13
Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds Grant 8,188,279 - Sinha , et al. May 29, 2	2012-05-29
THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS App 20110237797 - Sinha; Santosh C. ; et al.	2011-09-29
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same Grant 7,638,648 - Vasudevan , et al. December 29, 2	2009-12-29
Selective Subtype Alpha 2 Adrenergic Agents And Methods For Use Thereof App 20090197898 - Heidelbaugh; Todd M. ; et al.	2009-08-06
Disubstituted chalcone oximes as selective agonists of RAR.sub..gamma. retinoid receptors Grant 7,476,673 - Tsang , et al. January 13, 2	2009-01-13
Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B Grant 7,468,391 - Vasudevan , et al. December 23, 2	2008-12-23
Disubstituted chalcone oximes having RAR.gamma. retinoid receptor antagonist activity Grant 7,432,388 - Tsang , et al. October 7, 2	2008-10-07
Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity App 20080097119 - Tsang; Kwok Yin ; et al.	2008-04-24
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same App 20080004455 - Vasudevan; Jayasree ; et al.	2008-01-03
Disubstituted chalcone oximes having RAR.gamma. retinoid receptor antagonist activity Grant 7,253,319 - Tsang , et al. August 7, 2	2007-08-07
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same Grant 7,226,951 - Vasudevan , et al. June 5, 2	2007-06-05
5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity Grant 6,936,636 - Sinha , et al. August 30, 2	2005-08-30
Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B App 20050187298 - Vasudevan, Jayasree ; et al.	2005-08-25
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same App 20050176689 - Vasudevan, Jayasree ; et al.	2005-08-11
Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity App 20050165095 - Tsang, Kwok Yin ; et al.	2005-07-28
Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors App 20050148590 - Tsang, Kwok Yin ; et al.	2005-07-07
5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity App 20050004213 - Sinha, Santosh ; et al.	2005-01-06
[3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phen Yl And [3-(c5-14alkyl-2-oxo-1,2,3,4- Tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl Derivatives Having Anti-tumor Activity Grant 6,683,092 - Tsang , et al. January 27, 2	2004-01-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.